ALDX - Aldeyra Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue----
Cost of Revenue----
Gross Profit----
Operating Expenses
Research Development29,823.00716,302.56813,175.677,574.398
Selling General and Administrative9,876.1446,185.825,520.3084,414.709
Non Recurring----
Others----
Total Operating Expenses39,699.15122,488.38818,695.97811,989.107
Operating Income or Loss-39,699.151-22,488.388-18,695.978-11,989.107
Income from Continuing Operations
Total Other Income/Expenses Net805.906147.799-3.472-101.18
Earnings Before Interest and Taxes-39,699.151-22,488.388-18,695.978-11,989.107
Interest Expense-146.792-113.453-105.509-112.306
Income Before Tax-38,893.245-22,340.589-18,699.45-12,090.287
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-38,893.245-22,340.589-18,699.45-12,090.287
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-38,893.245-22,340.589-18,699.45-12,090.287
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-38,893.245-22,340.589-18,699.45-12,090.287